Nerve risks after weight loss drugs

A 2026 systematic review found 31 published cases of peripheral nerve problems linked in time to medicines used for weight loss, plus a separate cohort of 103 people. Most individual cases involved semaglutide or tirzepatide. The review cannot show how often these problems happen or prove that either medicine directly injured a nerve. It does show a pattern worth recognizing: substantial or rapid weight loss, sharp improvement in blood sugar, and reduced nutrition may each expose a different route to nerve damage^[1].

What the review found

The authors searched PubMed, Embase, and CINAHL from their start dates through 30 June 2026. Two reviewers screened records independently. From 2,510 records after duplicates were removed, they included 19 reports containing 31 individual cases and one cohort study with 103 people. All but one of the individual case reports had appeared since 2024^[1]. This is a systematic collection of published reports, not a randomized trial or an estimate of risk among everyone using these medicines.

Among the 31 individual cases, median weight loss was 20.4 kg, equal to 21.8% of starting body weight. The median rate was 3.7 kg per month, and symptoms began after a median of 150 days. Semaglutide or tirzepatide appeared in 83% of the cases, while 67% of the people had diabetes or prediabetes^[1]. Those figures describe a selected group that developed a problem and was written up. They do not mean that 83% of medicine users face nerve damage.

The most frequent diagnoses were fibular neuropathy in 10 cases, lumbosacral radiculoplexus neuropathy in nine, and distal symmetric polyneuropathy in seven^[1]. Fibular neuropathy affects the nerve that passes close to the outside of the knee and can cause weakness lifting the foot. Lumbosacral radiculoplexus neuropathy affects nerve roots and the network serving the hip and leg. Distal symmetric polyneuropathy usually begins in the feet with numbness, pain, or weakness on both sides.

Three routes may lead to nerve injury

The first route is mechanical. Fat and other tissue around the fibular nerve provide some protection where the nerve curves around the fibular head near the knee. Rapid loss of that padding can leave the nerve more vulnerable to pressure from leg crossing, prolonged positions, or ordinary contact. Two published tirzepatide cases described bilateral foot drop after rapid weight loss, which the authors called slimmer's paralysis^[3]. A case report can identify a plausible sequence, but it cannot separate the medicine from the speed and extent of weight change.

The second route concerns glucose control. In people with diabetes, a large fall in HbA1c, a measure of average blood sugar, can precede treatment induced neuropathy or lumbosacral radiculoplexus neuropathy. A Mayo Clinic case control study identified 26 people with 27 lumbosacral episodes after starting a GLP 1 receptor agonist. At symptom onset, median HbA1c had fallen by 2.4 percentage points and median weight loss was 13.9%^[2]. This association does not establish that the drug molecule itself attacked the nerves.

That Mayo study also identified 77 people with 82 common fibular neuropathy episodes. Their median weight loss was 15.7%, while their median HbA1c reduction was smaller at 1.2 percentage points. Compared with matched controls, GLP 1 receptor agonist users had higher odds of both diagnoses. The authors interpreted the lumbosacral pattern as more closely related to metabolic change and the fibular pattern as more influenced by weight loss and compression^[2]. Because the study was retrospective, unmeasured differences between users and controls may remain.

The third route is nutritional. Reduced food intake can make it harder to meet requirements for vitamins and minerals, especially when weight falls quickly or the starting diet is limited. Deficiencies of thiamine, vitamin B12, vitamin E, and copper can injure peripheral nerves. The review found that nutritional assessment was poorly documented and overt deficiency was uncommon in the published cases^[1]. Nutrition is therefore a credible contributor in some cases, not a proven explanation for the whole group.

What the evidence does not prove

The review cannot calculate incidence. Its evidence base is dominated by case reports, which are more likely to describe unusual or severe outcomes than routine treatment. Reporting may also rise when a medicine becomes widely used or when clinicians start watching for a suspected problem. The authors said peripheral nerve complications are expected to be uncommon given the small number of published cases, although the functional effects can be serious and recovery is not guaranteed^[1].

Direct toxicity is also not the leading explanation in the review. The authors noted evidence that GLP 1 receptor agonists may protect nerves through effects on inflammation and oxidative stress, and that controlled weight loss can improve existing neuropathy in some people^[1]. The competing findings make a simple claim that these medicines poison nerves hard to defend. A more cautious reading is that rapid physiological change can create risk in a susceptible person.

Symptoms need clinical assessment

New foot drop, marked weakness, or trouble walking needs prompt medical assessment. Numbness, burning pain, or tingling that spreads or persists also deserves attention. These symptoms have many possible causes, including diabetes itself, nerve compression, vitamin deficiency, spine disease, and inflammatory neuropathy. Timing alone cannot identify the cause.

Do not stop a prescribed medicine solely because of this review. Contact the prescribing clinician and describe when symptoms began, how quickly weight and blood sugar changed, and whether eating patterns changed. Readers can check our semaglutide overview and tirzepatide overview for medicine specific evidence and regulatory context. The review describes an uncommon signal that still deserves attention. New neurological symptoms during major weight or glucose change should not be dismissed.